Private biotech companies tend to be, well, private. That might explain why so many barely make a public peep after raising millions of dollars from venture capital firms. Few early-stage biotech companies in the Boston area issue more than a handful of press releases every year.

But that doesn’t mean the companies and their executives aren’t keeping busy. This time last year, resTORbio (TORC) and Neon Therapeutics (NTGN) were still private companies. KSQ Therapeutics had just raised a $76 million round in October 2017 — that company just raised another $80 million this September.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • one year in biotech drug development is not really indicative. You should do that kind of analysis of startups that made some noise 3-5 years ago. To see if they have something to show for, bankrupted or just closed down

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy